Linking Molecular Pathways and Large-Scale Computational Modeling to Assess Candidate Disease Mechanisms and Pharmacodynamics in Alzheimer's Disease

Abstract

Introduction While the prevalence of neurodegenerative diseases associated with dementia such as Alzheimer’s disease (AD) increases, our knowledge on the underlying mechanisms, outcome predictors, or therapeutic targets is limited. In this work, we demonstrate how computational multi-scale brain modelling links phenomena of different scales and therefore identifies potential disease mechanisms leading the way to improved diagnostics and treatment. Methods The Virtual Brain (TVB; thevirtualbrain.org ) neuroinformatics platform allows standardized large-scale structural connectivity-based simulations of whole brain dynamics. We provide proof of concept for a novel approach that quantitatively links the effects of altered molecular pathways onto neuronal population dynamics. As a novelty, we connect chemical compounds measured with positron emission tomography (PET) with neural function in TVB addressing the phenomenon of hyperexcitability in AD related to the protein amyloid beta (Abeta). We construct personalized virtual brains based on individual PET derived distributions of Abeta in patients with mild cognitive impairment (MCI, N=8) and Alzheimer’s Disease (AD, N=10) and in age-matched healthy controls (HC, N=15) using data from ADNI-3 data base ( http://adni.lni.usc.edu ). In the personalized virtual brains, individual Abeta burden modulates regional inhibition, leading to disinhibition and hyperexcitation with high Abeta loads. We analyze simulated regional neural activity and electroencephalograms (EEG). Results Known empirical alterations of EEG in patients with AD compared to HCs were reproduced by simulations. The virtual AD group showed slower frequencies in simulated local field potentials and EEG compared to MCI and HC groups. The heterogeneity of the Abeta load is crucial for the virtual EEG slowing which is absent for control models with homogeneous Abeta distributions. Slowing phenomena primarily affect the network hubs, independent of the spatial distribution of Abeta. Modeling the N-methyl-D-aspartate (NMDA) receptor antagonism of memantine in local population models, reveals potential functional reversibility of the observed large-scale alterations (reflected by EEG slowing) in virtual AD brains. Discussion We demonstrate how TVB enables the simulation of systems effects caused by pathogenetic molecular candidate mechanisms in human virtual brains.

References 147

1. 1.
   Infection of Fungi and Bacteria in Brain Tissue From Elderly Persons and Patients With Alzheimer’s Disease · 2018

   No notice
2. 2.

   Alzheimer's Association (2018 ). 2018 Alzheimer's disease facts and figures. Alzheimer's Dement. 14, 367–429.

   Not in our library10.1016/j.jalz.2018.02.001

3. 3.

   Babiloni C. Del Percio C. Caroli A. Salvatore E. Nicolai E. Marzano N.. (2016 ). Cortical sources of resting state EEG rhythms are related to brain hypometabolism in subjects with Alzheimer's disease: an EEG-PET study. Neurobiol. Aging 48, 122–134.

   Not in our library10.1016/j.neurobiolaging.2016.08.021

4. 4.

   Bannai T. Mano T. Chen X. Ohtomo G. Ohtomo R. Tsuchida T.. (2019 ). Chronic cerebral hypoperfusion shifts the equilibrium of amyloid beta oligomers to aggregation-prone species with higher molecular weight. Sci. Rep. 9:2827.

   Not in our library10.1038/s41598-019-39494-7

5. 5.

   Biogen (2019 ). Biogen and EISAI to discontinue phase 3 engage and emerge trials of aducanumab in Alzheimer's disease 2019 [04/01/2019]. Available online at: http://investors.biogen.com/news-releases/news-release-details/biogen-and-eisai-discontinue-phase-3-engage-and-emerge-trials

   Not in our library

6. 6.

   Blennow K. de Leon M. J. Zetterberg H. (2006 ). Alzheimer's disease. Lancet 368, 387–403.

   Not in our library10.1016/s0140-6736(06)69113-7

7. 7.

   Bloom G. S. (2014 ). Amyloid-β and tau: The trigger and bullet in Alzheimer disease pathogenesis. JAMA Neurol. 71, 505–508.

   Not in our library10.1001/jamaneurol.2013.5847

8. 8.

   Bojak I. Oostendorp T. F. Reid A. T. Kotter R. (2010 ). Connecting mean field models of neural activity to EEG and fMRI data. Brain Topogr. 23, 139–149.

   Not in our library10.1007/s10548-010-0140-3

9. 9.

   Braak H. Alafuzoff I. Arzberger T. Kretzschmar H. Del Tredici K. (2006 ). Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol. 112, 389–404.

   Not in our library10.1007/s00401-006-0127-z

10. 10.

    Braak H. Braak E. (1991 ). Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 82, 239–259.

    Not in our library10.1007/bf00308809

11. 11.

    Braak H. Braak E. (1997 ). Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol. Aging 18, 351–357.

    Not in our library10.1016/s0197-4580(97)00056-0

12. 12.

    Breakspear M. (2017 ). Dynamic models of large-scale brain activity. Nat. Neurosci. 20, 340–352.

    Not in our library10.1038/nn.4497

13. 13.

    Busche M. A. Chen X. Henning H. A. Reichwald J. Staufenbiel M. Sakmann B.. (2012 ). Critical role of soluble amyloid-beta for early hippocampal hyperactivity in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. U.S.A. 109, 8740–8745.

    Not in our library10.1073/pnas.1206171109

14. 14.

    Busche M. A. Eichhoff G. Adelsberger H. Abramowski D. Wiederhold K. H. Haass C.. (2008 ). Clusters of hyperactive neurons near amyloid plaques in a mouse model of Alzheimer's disease. Science 321, 1686–1689.

    Not in our library10.1126/science.1162844

15. 15.

    Cabral J. Kringelbach M. L. Deco G. (2017 ). Functional connectivity dynamically evolves on multiple time-scales over a static structural connectome: models and mechanisms. Neuroimage 160, 84–96.

    Not in our library10.1016/j.neuroimage.2017.03.045

16. 16.

    Celebi O. Uzdogan A. Oguz K. K. Has A. C. Dolgun A. Cakmakli G. Y.. (2016 ). Default mode network connectivity is linked to cognitive functioning and CSF Abeta1-42 levels in Alzheimer's disease. Arch. Gerontol. Geriatr. 62, 125–132.

    Not in our library10.1016/j.archger.2015.09.010

17. 17.

    Chen C. (2005 ). beta-Amyloid increases dendritic Ca2+ influx by inhibiting the A-type K+ current in hippocampal CA1 pyramidal neurons. Biochem. Biophys. Res. Commun. 338, 1913–1919.

    Not in our library10.1016/j.bbrc.2005.10.169

18. 18.
    Treatment effects between monotherapy of donepezil versus combination with memantine for Alzheimer disease: A meta-analysis. · 2017

    Not checked
19. 19.

    Chiao P. Bedell B. J. Avants B. Zijdenbos A. P. Grand'Maison M. O'Neill P.. (2019 ). Impact of reference and target region selection on amyloid PET SUV ratios in the phase 1b PRIME study of Aducanumab. J. Nucl. Med. 60, 100–106.

    Not in our library10.2967/jnumed.118.209130

20. 20.

    Clark C. M. Schneider J. A. Bedell B. J. Beach T. G. Bilker W. B. Mintun M. A.. (2011 ). Use of florbetapir-pet for imaging β-amyloid pathology. JAMA. 305, 275–283.

    Not in our library10.1001/jama.2010.2008

21. 21.

    David O. Friston K. J. (2003 ). A neural mass model for MEG/EEG:: coupling and neuronal dynamics. NeuroImage 20, 1743–1755.

    Not in our library10.1016/j.neuroimage.2003.07.015

22. 22.

    David O. Kiebel S. J. Harrison L. M. Mattout J. Kilner J. M. Friston K. J. (2006 ). Dynamic causal modeling of evoked responses in EEG and MEG. NeuroImage 30, 1255–1272.

    Not in our library10.1016/j.neuroimage.2005.10.045

23. 23.
    The Dynamic Brain: From Spiking Neurons to Neural Masses and Cortical Fields · 2008

    No notice
24. 24.
    The dynamics of resting fluctuations in the brain: metastability and its dynamical cortical core · 2017

    No notice
25. 25.

    Dierks T. Jelic V. Pascual-Marqui R. D. Wahlund L. Julin P. Linden D. E.. (2000 ). Spatial pattern of cerebral glucose metabolism (PET) correlates with localization of intracerebral EEG-generators in Alzheimer's disease. Clin. Neurophysiol. 111, 1817–1824.

    Not in our library10.1016/s1388-2457(00)00427-2

26. 26.

    Doggrell S. A. (2018 ). Grasping at straws: the failure of solanezumab to modify mild Alzheimer's disease. Expert Opin. Biol. Ther. 18, 1189–1192.

    Not in our library10.1080/14712598.2018.1543397

27. 27.

    Falcon M. I. Riley J. D. Jirsa V. McIntosh A. R. Elinor Chen E. Solodkin A. (2016 ). Functional mechanisms of recovery after chronic stroke: modeling with the virtual brain. eNeuro 3:ENEURO.0158-15.2016.

    Not in our library10.1523/eneuro.0158-15.2016

28. 28.

    Falcon M. I. Riley J. D. Jirsa V. McIntosh A. R. Shereen A. D. Chen E. E.. (2015 ). The virtual brain: modeling biological correlates of recovery after chronic stroke. Front. Neurol. 6:228.

    Not in our library10.3389/fneur.2015.00228

29. 29.

    Freeman W. J. (ed). (1975 ). Mass Action in the Nervous System. San Diego, CA: Academic Press.

    Not in our library

30. 30.

    Fruchterman T. M. J. Reingold E. M. (1991 ). Graph drawing by force-directed placement. Softw. Pract. Exper. 21, 1129–1164.

    Not in our library10.1002/spe.4380211102

31. 31.

    Furukawa K. Barger S. W. Blalock E. M. Mattson M. P. (1996 ). Activation of K+ channels and suppression of neuronal activity by secreted beta-amyloid-precursor protein. Nature 379, 74–78.

    Not in our library10.1038/379074a0

32. 32.
    Impact of the biological definition of Alzheimer’s disease using amyloid, tau and neurodegeneration (ATN): what about the role of vascular changes, inflammation, Lewy body pathology? · 2018

    Not checked
33. 33.
    Noise during Rest Enables the Exploration of the Brain's Dynamic Repertoire · 2008

    No notice
34. 34.

    Glasser M. F. Coalson T. S. Robinson E. C. Hacker C. D. Harwell J. Yacoub E.. (2016 ). A multi-modal parcellation of human cerebral cortex. Nature 536, 171–178.

    Not in our library10.1038/nature18933

35. 35.

    Glasser M. F. Sotiropoulos S. N. Wilson J. A. Coalson T. S. Fischl B. Andersson J. L.. (2013 ). The minimal preprocessing pipelines for the human connectome project. Neuroimage 80, 105–124.

    Not in our library10.1016/j.neuroimage.2013.04.127

36. 36.

    Good T. A. Smith D. O. Murphy R. M. (1996 ). Beta-amyloid peptide blocks the fast-inactivating K+ current in rat hippocampal neurons. Biophys. J. 70, 296–304.

    Not in our library10.1016/s0006-3495(96)79570-x

37. 37.

    Grienberger C. Rochefort N. L. Adelsberger H. Henning H. A. Hill D. N. Reichwald J. (2012 ). Staged decline of neuronal function in vivo in an animal model of Alzheimers disease. Nat. Commun. 3:774

    Not in our library10.1038/ncomms1783

38. 38.
    Roles of tau protein in health and disease · 2017

    No notice
39. 39.

    Hardy J. Selkoe D. J. (2002 ). The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297, 353–356.

    Not in our library10.1126/science.1072994

40. 40.

    Hazra A. Gu F. Aulakh A. Berridge C. Eriksen J. L. Ziburkus J. (2013 ). Inhibitory neuron and hippocampal circuit dysfunction in an aged mouse model of Alzheimer's disease. PLoS ONE 8:e64318.

    Not in our library10.1371/journal.pone.0064318

Cited by papers we hold 3

• Whole-Brain Network Models: From Physics to Bedside · 2022
  Not checked
• Increased Excursions to Functional Networks in Schizophrenia in the Absence of Task · 2022
  Not checked
• Quantitative systems pharmacology in neuroscience: Novel methodologies and technologies · 2021
  Not checked

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.